This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
Pacira (PCRX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 21.92% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
by Zacks Equity Research
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
by Zacks Equity Research
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacira (PCRX) Matches Q4 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 0% and 0.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 6.25% and 1.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
by Zacks Equity Research
Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
by Zacks Equity Research
The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated
by Zacks Equity Research
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.
Pacira (PCRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Pacira (PCRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.